Strategic Partnership Teva Canada has demonstrated a willingness to form strategic partnerships, exemplified by the February 2026 collaboration with Novartis Canada to relaunch Mayzent for SPMS in Canada. This indicates openness to co-development and co-marketing opportunities with large global players to expand specialty medicines reach.

Specialty Growth The company sits at the intersection of generics and specialty medicines, with a global CNS, respiratory, oncology and women’s health portfolio. This creates cross-sell potential into hospitals, clinics and payer networks seeking integrated generic and branded options for chronic conditions.

Leadership Momentum Recent leadership change with a new General Manager in 2024 signals potential strategic pivots, new customer engagement approaches, and renewed sales initiatives that can be aligned with target accounts and expanded product categories.

Canadian Footprint With a long-standing presence since 1965 and a workforce of over a thousand, Teva Canada emphasizes local manufacturing and market access. Opportunities exist to position regional supply, faster time-to-market products, and adherence-friendly programs for Canadian healthcare buyers.

Digital and Access Programs Teva Canada leverages digital tools and patient/physician support platforms (eg Life Effects) and has invested in device-enabled therapies (autoinjectors) and inhaler products. This suggests upsell opportunities around patient adherence programs, digital engagement, and device-enabled treatment pathways for chronic diseases.